409 related articles for article (PubMed ID: 25013764)
1. Immunological dysregulation in multiple myeloma microenvironment.
Romano A; Conticello C; Cavalli M; Vetro C; La Fauci A; Parrinello NL; Di Raimondo F
Biomed Res Int; 2014; 2014():198539. PubMed ID: 25013764
[TBL] [Abstract][Full Text] [Related]
2. Multiple Myeloma and the Immune Microenvironment.
Kawano Y; Roccaro AM; Ghobrial IM; Azzi J
Curr Cancer Drug Targets; 2017; 17(9):806-818. PubMed ID: 28201978
[TBL] [Abstract][Full Text] [Related]
3. The Role of Marrow Microenvironment in the Growth and Development of Malignant Plasma Cells in Multiple Myeloma.
Giannakoulas N; Ntanasis-Stathopoulos I; Terpos E
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33923357
[TBL] [Abstract][Full Text] [Related]
4. Monocytic Myeloid Derived Suppressor Cells in Hematological Malignancies.
Palumbo GA; Parrinello NL; Giallongo C; D'Amico E; Zanghì A; Puglisi F; Conticello C; Chiarenza A; Tibullo D; Raimondo FD; Romano A
Int J Mol Sci; 2019 Nov; 20(21):. PubMed ID: 31683978
[TBL] [Abstract][Full Text] [Related]
5. Decitabine shows potent anti-myeloma activity by depleting monocytic myeloid-derived suppressor cells in the myeloma microenvironment.
Zhou J; Shen Q; Lin H; Hu L; Li G; Zhang X
J Cancer Res Clin Oncol; 2019 Feb; 145(2):329-336. PubMed ID: 30426212
[TBL] [Abstract][Full Text] [Related]
6. Alterations in the Transcriptional Programs of Myeloma Cells and the Microenvironment during Extramedullary Progression Affect Proliferation and Immune Evasion.
Ryu D; Kim SJ; Hong Y; Jo A; Kim N; Kim HJ; Lee HO; Kim K; Park WY
Clin Cancer Res; 2020 Feb; 26(4):935-944. PubMed ID: 31558476
[TBL] [Abstract][Full Text] [Related]
7. Cell autonomous and microenvironmental regulation of tumor progression in precursor states of multiple myeloma.
Manier S; Kawano Y; Bianchi G; Roccaro AM; Ghobrial IM
Curr Opin Hematol; 2016 Jul; 23(4):426-33. PubMed ID: 27101529
[TBL] [Abstract][Full Text] [Related]
8. CD28 expressed on malignant plasma cells induces a prosurvival and immunosuppressive microenvironment.
Nair JR; Carlson LM; Koorella C; Rozanski CH; Byrne GE; Bergsagel PL; Shaughnessy JP; Boise LH; Chanan-Khan A; Lee KP
J Immunol; 2011 Aug; 187(3):1243-53. PubMed ID: 21715687
[TBL] [Abstract][Full Text] [Related]
9. Adhesion molecules--The lifelines of multiple myeloma cells.
Katz BZ
Semin Cancer Biol; 2010 Jun; 20(3):186-95. PubMed ID: 20416379
[TBL] [Abstract][Full Text] [Related]
10. The bone marrow microenvironment enhances multiple myeloma progression by exosome-mediated activation of myeloid-derived suppressor cells.
Wang J; De Veirman K; De Beule N; Maes K; De Bruyne E; Van Valckenborgh E; Vanderkerken K; Menu E
Oncotarget; 2015 Dec; 6(41):43992-4004. PubMed ID: 26556857
[TBL] [Abstract][Full Text] [Related]
11. MicroRNAs: Novel Crossroads between Myeloma Cells and the Bone Marrow Microenvironment.
Raimondi L; De Luca A; Morelli E; Giavaresi G; Tagliaferri P; Tassone P; Amodio N
Biomed Res Int; 2016; 2016():6504593. PubMed ID: 26881223
[TBL] [Abstract][Full Text] [Related]
12. Extracellular vesicle cross-talk in the bone marrow microenvironment: implications in multiple myeloma.
Wang J; Faict S; Maes K; De Bruyne E; Van Valckenborgh E; Schots R; Vanderkerken K; Menu E
Oncotarget; 2016 Jun; 7(25):38927-38945. PubMed ID: 26950273
[TBL] [Abstract][Full Text] [Related]
13. The microenvironment and molecular biology of the multiple myeloma tumor.
Lemaire M; Deleu S; De Bruyne E; Van Valckenborgh E; Menu E; Vanderkerken K
Adv Cancer Res; 2011; 110():19-42. PubMed ID: 21704227
[TBL] [Abstract][Full Text] [Related]
14. Bone marrow myeloid cells in regulation of multiple myeloma progression.
Herlihy SE; Lin C; Nefedova Y
Cancer Immunol Immunother; 2017 Aug; 66(8):1007-1014. PubMed ID: 28378067
[TBL] [Abstract][Full Text] [Related]
15. Role of Immunotherapy in Targeting the Bone Marrow Microenvironment in Multiple Myeloma: An Evolving Therapeutic Strategy.
Chung C
Pharmacotherapy; 2017 Jan; 37(1):129-143. PubMed ID: 27870103
[TBL] [Abstract][Full Text] [Related]
16. Bone Marrow Stromal Cells-Induced Drug Resistance in Multiple Myeloma.
Ria R; Vacca A
Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31963513
[TBL] [Abstract][Full Text] [Related]
17. Bone marrow microenvironment in multiple myeloma progression.
Manier S; Sacco A; Leleu X; Ghobrial IM; Roccaro AM
J Biomed Biotechnol; 2012; 2012():157496. PubMed ID: 23093834
[TBL] [Abstract][Full Text] [Related]
18. Osteoclast Immunosuppressive Effects in Multiple Myeloma: Role of Programmed Cell Death Ligand 1.
Tai YT; Cho SF; Anderson KC
Front Immunol; 2018; 9():1822. PubMed ID: 30147691
[TBL] [Abstract][Full Text] [Related]
19. N-cadherin-mediated interaction with multiple myeloma cells inhibits osteoblast differentiation.
Groen RW; de Rooij MF; Kocemba KA; Reijmers RM; de Haan-Kramer A; Overdijk MB; Aalders L; Rozemuller H; Martens AC; Bergsagel PL; Kersten MJ; Pals ST; Spaargaren M
Haematologica; 2011 Nov; 96(11):1653-61. PubMed ID: 21828122
[TBL] [Abstract][Full Text] [Related]
20. Transcriptomic profile induced in bone marrow mesenchymal stromal cells after interaction with multiple myeloma cells: implications in myeloma progression and myeloma bone disease.
Garcia-Gomez A; De Las Rivas J; Ocio EM; Díaz-Rodríguez E; Montero JC; Martín M; Blanco JF; Sanchez-Guijo FM; Pandiella A; San Miguel JF; Garayoa M
Oncotarget; 2014 Sep; 5(18):8284-305. PubMed ID: 25268740
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]